Comparative Pharmacology
Head-to-head clinical analysis: CELESTONE versus STERI STAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELESTONE versus STERI STAT.
CELESTONE vs STERI-STAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Celestone (betamethasone) is a corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and antiproliferative effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
Betamethasone (Celestone) 0.6-7.2 mg/day orally in divided doses; 0.6-9.0 mg/day IM or IV as betamethasone sodium phosphate; dose adjusted based on severity.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
None Documented
None Documented
Terminal elimination half-life of betamethasone (active component) is 36-54 hours (mean ~44 hours) in adults, providing sustained adrenal suppression.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal: 75-90% as metabolites (glucuronides and sulfates) and <5% unchanged; biliary/fecal: 10-25%.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid